Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Akouos, Inc. (AKUS : NSDQ)
 
 • Company Description   
Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company's product candidate includes AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos, Inc. is based in Boston, Massachusetts.

Number of Employees: 103

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.85 Daily Weekly Monthly
20 Day Moving Average: 220,689 shares
Shares Outstanding: 34.63 (millions)
Market Capitalization: $98.68 (millions)
Beta: 1.58
52 Week High: $15.26
52 Week Low: $2.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.58% -4.28%
12 Week -48.09% -41.66%
Year To Date -66.47% -59.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
645 SUMMER STREET SUITE 200
-
BOSTON,MA 02210
USA
ph: 857-410-1818
fax: -
investors@akouos.com http://www.akouos.com
 
 • General Corporate Information   
Officers
Emmanuel Simons - President and Chief Executive Officer
Arthur O. Tzianabos - Chairman of the Board
Sachiyo Minegishi - Chief Financial Officer
Edward Mathers - Director
Kush M. Parmar - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00973J101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 34.63
Most Recent Split Date: (:1)
Beta: 1.58
Market Capitalization: $98.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.08 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 12.28% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.47
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -65.96%
vs. Previous Quarter: -8.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -40.01
12/31/21 - -32.61
09/30/21 - -26.06
ROA
03/31/22 - -33.97
12/31/21 - -28.54
09/30/21 - -23.41
Current Ratio
03/31/22 - 11.39
12/31/21 - 14.06
09/30/21 - 19.40
Quick Ratio
03/31/22 - 11.39
12/31/21 - 14.06
09/30/21 - 19.40
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.04
12/31/21 - 6.77
09/30/21 - 7.43
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©